22 October 2024 The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).
Although no treatments are currently approved for non-alcoholic steatohepatitis (NASH), quite a number or compounds are progressing in clinical development that hopefully will change this situation, and lead to strong market growth. 2 November 2018
The Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the US Food and Drug Administration (FDA), yesterday reviewed Alkermes New Drug Application (NDA) for ALKS-5461 (buprenorphine/samidorphan). 2 November 2018
Danish diabetes care giant Novo Nordisk this morning released financials, showing that sales for the first nine months of 2018 had decreased by 2% in Danish kroner and increased 4% in local currencies to 82.1 billion Danish kroner ($12.52 billion). 1 November 2018
The Institute for Clinical and Economic Review (ICER) is to consider what might constitute a fair price for two drug candidates that are of great importance to the companies developing them. 1 November 2018
AstraZeneca offered the UK government a reminder – as if any were needed – of what is at stake in Brexit negotiations with the European Union (EU) this month by saying that it was freezing its UK investments until clarity is provided. 31 October 2018
Michel Pettigrew, the most senior officer at privately-held drugmaker Ferring, is to retire at the end of the year, the Switzerland-based company has announced. 31 October 2018
The China Alliance for Rare Diseases (CARD) has formally been launched, in Beijing. The group which is comprised of stakeholders from many leading institutions in China, is part of efforts to promote the development of rare disease therapies and treatment access in the country. 31 October 2018
London-listed GlaxoSmithKline has released an upbeat financial results statement for the third quarter of 2018, posting group sales of £8.1 billion ($10.3 billion), a 3% increase on the same period last year, including £4.2 billion from the pharmaceuticals division. 31 October 2018
The partnership agreement for sales and information provision activities for the lyophilized hemophilus influenza vaccine type b “ActHIB” between Daiichi Sankyo and French major Sanofi will be terminated, the Japanese drugmaker announced today. 31 October 2018
ViiV Healthcare has announced positive headline results from its global, Phase III FLAIR (First Long-Acting Injectable Regimen) study of a long-acting, injectable two-drug regimen (2DR) for the treatment of HIV. 31 October 2018
Italian drugmaker Recordati saw its shares gain 2.54% to 31.07 euros yesterday, after it released financial results for the first nine months of 2018. 31 October 2018
Alkermes has published Phase III data for ALKS 5461 (buprenorphine/samidorphan) in the adjunctive treatment of major depressive disorder (MDD). 30 October 2018
Japan’s Astellas Pharma and USA-based FibroGen have presented Phase III data from two studies looking at roxadustat in the treatment of anemia associated with Chronic Kidney Disease (CKD). 30 October 2018
As part of its strategy to focus on core therapeutic areas, AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. 30 October 2018
Ireland-headquartered Allergan today reported its third quarter 2018 financials, showing that generally accepted accounting principles (GAAP) net revenues were $3.91 billion, a 3.0 % decrease from the prior year quarter, but above the FactSet consensus of $3.89 billion. 30 October 2018
A new drug for antiretroviral therapy is undergoing clinical trials at the Central Research Institute of Epidemiology of the Russian Federal Service on Surveillance for Consumer rights protection and human well-being (Rospotrebnadzor). 30 October 2018
For the era of personalized therapies to truly arrive, industry observers often express the view that pharma will have to improve its understanding not just of biology and medicines, but also of certain new technologies that are likely to determine companies’ future way of working. 30 October 2018
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Vertex Pharmaceuticals on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain. 21 October 2024
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Angelini Pharma, part of Italy’s Angelini Industries, has entered into an exclusive option agreement with South Korea-based Cureverse for the global development and commercialization of a clinical-stage brain health asset. 21 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.